Biomea Fusion (BMEA) Operating Expenses (2020 - 2026)
Biomea Fusion (BMEA) posted Operating Expenses of $12.8 million for Q1 2026, up 9.0% sequentially from $11.7 million in Q4 2025, and down 57.01% YoY from $29.7 million in Q1 2025.
Biomea Fusion (BMEA) Operating Expenses (2020 - 2026) Analysis & Trends
Biomea Fusion has reported Operating Expenses for 7 years, with the latest figure at $12.8 million in Q1 2026.
- Quarterly Operating Expenses fell 57.01% year-over-year to $12.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $66.6 million (down 49.84% YoY) and the FY2025 annual result came in at $83.5 million, down 42.03% from the prior year.
- Operating Expenses improved to $12.8 million in Q1 2026 per BMEA's latest filing, from $11.7 million in the prior quarter.
- Over five years, Operating Expenses peaked at $41.1 million in Q1 2024 and troughed at $11.7 million in Q4 2025.
- A 5-year average of $26.5 million and a median of $27.7 million in 2023 frame the typical range for Operating Expenses.
- The sharpest annual moves came in 2022 and 2025: Operating Expenses soared 180.01% in 2022, then plunged 61.03% in 2025.
- Over 5 years, Operating Expenses stood at $26.3 million in 2022, then surged by 42.06% to $37.3 million in 2023, then slipped by 19.43% to $30.1 million in 2024, then slumped by 61.03% to $11.7 million in 2025, then climbed by 9.0% to $12.8 million in 2026.
- According to Business Quant data, Operating Expenses over the past three periods registered $12.8 million, $11.7 million, and $20.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 2.89 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 960.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 1.21 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 1.06 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -784.57 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 427.03 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 541.02 Mn |
| 10 | Biomea Fusion | 97.69 Mn | 97.69 Mn | - | 12.77 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 12.77 Mn |
| Mar 31, 2026 | 12.77 Mn |
| Dec 31, 2025 | 11.72 Mn |
| Sep 30, 2025 | 20.81 Mn |
| Jun 30, 2025 | 21.28 Mn |
| Mar 31, 2025 | 29.71 Mn |
| Dec 31, 2024 | 30.07 Mn |
| Sep 30, 2024 | 34.04 Mn |
| Jun 30, 2024 | 38.90 Mn |
| Mar 31, 2024 | 41.06 Mn |
| Dec 31, 2023 | 37.33 Mn |
| Sep 30, 2023 | 31.12 Mn |
| Jun 30, 2023 | 27.66 Mn |
| Mar 31, 2023 | 30.03 Mn |
| Dec 31, 2022 | 26.28 Mn |
| Sep 30, 2022 | 23.48 Mn |
| Jun 30, 2022 | 17.47 Mn |
| Mar 31, 2022 | 16.40 Mn |
| Dec 31, 2021 | 14.74 Mn |
| Sep 30, 2021 | 12.64 Mn |